© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 10, 756-761,
May 17, 1995
© 1995 Oxford University Press
Differential Inactivation of CDKN2 and Rb Protein in Non—Small-Cell and Small-Cell Lung Cancer Cell Lines
NCI Navy Medical Oncology Branch, Division of Cancer Treatment, National Cancer Institute Bethesda, Md
Biostatistics and Data Management Section, Division of Cancer Treatment, National Cancer Institute Bethesda, Md
Myriad Genetics, Inc. Salt Lake City, Utah.
Correspondence to: Michael J. Kelley, M.D., NCI-Navy Medical Oncology Branch, Bldg. 8, Rm. 5105, National Naval Medical Center, Bethesda, MD 20889–5105.
Background: The CDKN2 gene encodes the human cyclin-dependent kinase 4 inhibitor. This inhibitor protein is believed to be a tumor suppressor that plays an essential role in cell cycle regulation. One half of all cancer cell lines and one fourth of lung cancer cell lines examined to date contain homozygous deletions (i.e., both alleles lost) of CDKN2. However, the relative frequency of homozygous CDKN2 deletions in non-small-cell lung cancers (NSCLC) and in small-cell lung cancers (SCLC) has not been determined. Inactivation or loss of another tumor suppressor encoded by the retinoblastoma gene (the Rb protein) is more common in SCLC than in NSCLC. Purpose: We measured the frequency of homozygous CDKN2 deletions in 77 NSCLC and in 93 SCLC tumor cell lines. In addition, possible associations were explored between CDKN2 gene loss, the presence or absence of Rb protein, and the clinical status of lung cancer patients. Methods: DNA was isolated from each tumor cell line and from the primary tumor and normal tissue of one NSCLC patient. Sequences corresponding to exons 1 and 2 of the CDKN2 gene were amplified by use of the polymerase chain reaction, and the resulting amplification products were analyzed by agarose gel electrophoresis and DNA blotting. Genomic DNA blotting was also used to evaluate CDKN2 gene deletions. The frequency of homozygous CDKN2 loss and the presence or absence of functional Rb protein (reported previously) in the cell lines were compared. Results: Homozygous deletion of CDKN2 was detected in 18 (23%) of 77 cell lines established from patients with NSCLC, compared with one (1%) of 93 cell lines established from patients with SCLC (P<.001). No CDKN2 gene loss was observed in the normal tissue of an NSCLC patient whose tumor cell line showed homozygous deletion of the gene; however, the primary tumor from this patient had evidence of CDKN2 loss. Homozygous CDKN2 deletion was detected in 13 (28%) of 46 tumor cell lines from patients with stage III or stage IV NSCLC, compared with zero of 10 tumor cell lines from patients with stage I or stage II NSCLC. Coincident loss of CDKN2 genes and functional Rb protein was rarely observed (in two of 135 cell lines). Conclusion: The frequency of homozygous CDKN2 gene deletion in NSCLC cell lines is greater than that observed for any other known, or candidate, tumor suppressor gene. Implication: Further study of the role of CDKN2 gene alteration in the pathogenesis of NSCLC is needed. [J Natl Cancer Inst 87: 756–761, 1995]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Burke, D. B. Flieder, D. G. Guinee, E. Brambilla, A. N. Freedman, W. P. Bennett, R. T. Jones, A. Borkowski, N. A. Caporaso, M. Fleming, et al. Prognostic Implications of Molecular and Immunohistochemical Profiles of the Rb and p53 Cell Cycle Regulatory Pathways in Primary Non-Small Cell Lung Carcinoma Clin. Cancer Res., January 1, 2005; 11(1): 232 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sanchez-Cespedes, P. Parrella, M. Esteller, S. Nomoto, B. Trink, J. M. Engles, W. H. Westra, J. G. Herman, and D. Sidransky Inactivation of LKB1/STK11 Is a Common Event in Adenocarcinomas of the Lung Cancer Res., July 1, 2002; 62(13): 3659 - 3662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Toyooka, Y. Fukuyama, I. I. Wistuba, M. S. Tockman, J. D. Minna, and A. F. Gazdar Differential Expression of FEZ1/LZTS1 Gene in Lung Cancers and Their Cell Cultures Clin. Cancer Res., July 1, 2002; 8(7): 2292 - 2297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Toyooka, K. O. Toyooka, R. Maruyama, A. K. Virmani, L. Girard, K. Miyajima, K. Harada, Y. Ariyoshi, T. Takahashi, K. Sugio, et al. DNA Methylation Profiles of Lung Tumors Mol. Cancer Ther., November 1, 2001; 1(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. I. Shapiro, J. G. Supko, A. Patterson, C. Lynch, J. Lucca, P. F. Zacarola, A. Muzikansky, J. J. Wright, T. J. Lynch Jr., and B. J. Rollins A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer Clin. Cancer Res., June 1, 2001; 7(6): 1590 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Tang, F. R. Khuri, J. J. Lee, B. L. Kemp, D. Liu, W. K. Hong, and L. Mao Hypermethylation of the Death-Associated Protein (DAP) Kinase Promoter and Aggressiveness in Stage I Non-Small-Cell Lung Cancer J Natl Cancer Inst, September 20, 2000; 92(18): 1511 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. N. ROM, J. G. HAY, T. C. LEE, Y. JIANG, and K.-M. TCHOU-WONG Molecular and Genetic Aspects of Lung Cancer Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1355 - 1367. [Full Text]
|
|
|
|
 |
|
 P. A. Bunn Jr., A. Soriano, G. Johnson, and L. Heasley New Therapeutic Strategies for Lung Cancer : Biology and Molecular Biology Come of Age Chest, April 1, 2000; 117 (2009): 163S - 168S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Fong, Y. Sekido, and J. D. Minna MOLECULAR PATHOGENESIS OF LUNG CANCER J. Thorac. Cardiovasc. Surg., December 1, 1999; 118(6): 1136 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kubo, K. Nakagawa, R. K. Varma, N. K. Conrad, J. Q. Cheng, W.-C. Lee, J. R. Testa, B. E. Johnson, F. J. Kaye, and M. J. Kelley The p16 Status of Tumor Cell Lines Identifies Small Molecule Inhibitors Specific for Cyclin-dependent Kinase 4 Clin. Cancer Res., December 1, 1999; 5(12): 4279 - 4286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Mack, D. R. Gandara, C. Bowen, M. J. Edelman, T. Paglieroni, J. B. Schnier, E. P. Gelmann, and P. H. Gumerlock RB Status as a Determinant of Response to UCN-01 in Non-Small Cell Lung Carcinoma Clin. Cancer Res., September 1, 1999; 5(9): 2596 - 2604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Brambilla, S. Gazzeri, D. Moro, S. Lantuejoul, S. Veyrenc, and C. Brambilla Alterations of Rb Pathway (Rb-p16INK4-Cyclin D1) in Preinvasive Bronchial Lesions Clin. Cancer Res., February 1, 1999; 5(2): 243 - 250. [Abstract] [Full Text] [PDF]
|
|